Ken Griffin Alpine Immune Sciences, Inc. Transaction History

Citadel Advisors LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$17.75 - $41.6 $13 Million - $30.5 Million	-732,378 Reduced 83.68%	142,879 $5.66 Million
Q4 2023 Feb 14, 2024	BUY	$8.54 - $20.22 $7.23 Million - $17.1 Million	847,083 Added 3006.61%	875,257 $16.7 Million
Q3 2023 Nov 14, 2023	SELL	$10.13 - $13.98 $258,811 - $357,175	-25,549 Reduced 47.56%	28,174 $322,000
Q2 2023 Aug 14, 2023	BUY	$6.84 - $11.91 $367,465 - $639,840	53,723 New	53,723 $552,000
Q4 2022 Feb 14, 2023	BUY	$5.45 - $7.35 $115,561 - $155,849	21,204 New	21,204 $155,000

56.2K

Ticker ALPN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 44,006,700
Description
Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.